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Abstract
While the initial pathology of Parkinson’s disease and other α-
synucleinopathies is often confined to circumscribed brain regions,
it can spread and progressively affect adjacent and distant brain
locales. This process may be controlled by cellular receptors of α-
synuclein fibrils, one of which was proposed to be the LAG3
immune checkpoint molecule. Here, we analysed the expression
pattern of LAG3 in human and mouse brains. Using a variety of
methods and model systems, we found no evidence for LAG3
expression by neurons. While we confirmed that LAG3 interacts
with α-synuclein fibrils, the specificity of this interaction appears
limited. Moreover, overexpression of LAG3 in cultured human
neural cells did not cause any worsening of α-synuclein pathology
ex vivo. The overall survival of A53T α-synuclein transgenic mice
was unaffected by LAG3 depletion, and the seeded induction of α-
synuclein lesions in hippocampal slice cultures was unaffected by
LAG3 knockout. These data suggest that the proposed role of LAG3
in the spreading of α-synucleinopathies is not universally valid.
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Introduction
Lymphocyte-activation gene 3 (LAG3) is an inhibitory immune
checkpoint molecule. It may represent a therapeutic target against
solid and haematologic tumours (Nguyen & Ohashi, 2015; Andrews
et al, 2017; Ascierto et al, 2017; Lichtenegger et al, 2018; Lim et al,
2020; Rohatgi et al, 2020). LAG3 is expressed in activated T cells,
natural killer cells and dendritic cells (Triebel et al, 1990; Huard
et al, 1994, 1997; Hannier & Triebel, 1999; Workman et al, 2002,
2009; Maçon-Lemaı̂tre & Triebel, 2005; Camisaschi et al, 2010), and
these findings support its role in the immune system. More recently,
it was proposed that LAG3 may function in the central nervous
system (CNS) as a receptor of pathogenic α-synuclein assemblies,
which are causally involved in Parkinson’s disease (PD). Mice
devoid of LAG3 were reported to develop lower levels of phosphory-
lated α-synuclein than wild-type mice upon inoculation with
α-synuclein pre-formed fibrils (PFFs). Furthermore, treatment with
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anti-LAG3 antibodies attenuated the spread of pathological
α-synuclein and drastically lowered the aggregation in vitro (Mao et
al, 2016).
This finding, if confirmed, could have far-reaching implications.
PD is a common neurodegenerative movement disorder (Beitz,
2014; Deweerdt, 2016; Jankovic, 2017) that causes a high level of
suffering to the affected patients and their families. Histologically,
PD is characterized by α-synuclein inclusions known as Lewy bodies
whose accumulation is associated with neurodegeneration (Dickson,
2012; Mullin & Schapira, 2015; Corbille et al, 2016). These inclu-
sions affect the Substantia nigra and other mesencephalic regions as
well as, in some cases, the amygdala and neocortex (Dickson,
2018). Growing evidence suggests that α-synuclein aggregates
spread from cell to cell (Volpicelli-Daley et al, 2011; Volpicelli-Daley
et al, 2014), by a “prionoid” process of templated conversion
(Aguzzi, 2009; Jucker & Walker, 2018; Kara et al, 2018; Henderson
et al, 2019; Karpowicz et al, 2019; Uemura et al, 2020; Kara et al,
2021). It is thought that interrupting transmission of α-synuclein
may slow down or abrogate the disease course. Although a more
general pathogenic role for LAG3 in the progression of prion disor-
ders has been ruled out (Liu et al, 2018), impairing the binding of
α-synuclein fibrils to neuronal LAG3 may still constitute an attrac-
tive target for small drugs or immunotherapy of PD.
Here, we have analysed LAG3 expression and α-synuclein bind-
ing in mouse and human model systems. Additionally, we studied
the propagation of pre-formed fibrils (PFFs) of α-synuclein in neural
stem cell (NSC)-derived neural cultures in the presence or absence
of LAG3. Finally, we have investigated the impact of LAG3 on
survival in ASYNA53T transgenic mice (a model of Parkinson’s
disease) expressing wild-type LAG3 as well as hemizygous or
homozygous deletions thereof. We failed to detect neuronal expres-
sion of LAG3 and were unable to establish any role for LAG3 in α-
synucleinopathies in vitro and in vivo.
Results
Absence of endogenous LAG3 from neuronal cell lines,
NSC-derived neural cultures and human brain samples
The sequence homology between human and mouse LAG3 proteins
is < 70%. This may limit the cross-species reactivity of anti-LAG3
antibodies. We therefore asked whether available antibodies bind
the extracellular domain of human or mouse LAG3. We coated 384-
well microplates with recombinant human LAG323-450 or mouse
LAG324-442 and measured binding of 8 commercially available anti-
LAG3 antibodies by enzyme-linked immunosorbent assay (ELISA)
(Fig 1A). All antibodies except LSB15026 bound exclusively human
or mouse LAG3, but not both. This suggests that many relevant
LAG3 epitopes differ between species. Western blot analysis con-
firmed that the mouse monoclonal antibody 4-10-C9 used in Mao et
al (2016) did not bind human LAG3 as either recombinant protein
or overexpressed by lentivirally transduced murine primary
cultures, whereas murine LAG3 was detected (Fig 1B).
We then attempted to identify a human neural cell line that
expresses LAG3. We therefore immunoblotted five different human
cell lines and included activated T lymphocytes for control. We did
not detect bands specific for LAG3 in any of the human glial,
neuronal or control (HEK293T) cell lines (Fig 1C). We then induced
differentiation of human neural stem cells (NSC) for which we had
available concomitant single-cell RNA sequencing (scRNAseq) data
(Hruska-Plochan et al, 2021), and immunoblotted their lysates. For
control, NSC-derived cultures were additionally transduced with a
lentiviral plasmid encoding human LAG3. Western blotting did not
reveal any LAG3-specific bands in non-induced cultures (Fig 1D),
and scRNAseq yielded only minimal counts for the LAG3 transcript
in neurons (N), astrocytes (AST) and mixed glial (MG) cells (Fig 1
E). The counts observed for LAG3 in these cell types were compara-
ble to those of the other T-cell checkpoints, T-cell immunoreceptor
with Ig and ITIM domains (TIGIT) and T-cell immunoglobulin and
mucin domain-containing protein 3 (TIM3 or HAVCR2) whereas
neuronal or astrocytic markers displayed the expected transcrip-
tional profiles (Fig EV1A). We also confirmed the absence of LAG3
signal in immunoblots of dopaminergic neuronal cultures from
control lines and PD patients carrying a N370S polymorphism in the
glucocerebrosidase (GBA) gene (Fig EV1B and F), further suggesting
that LAG3 is not expressed in neurons.
We next investigated whether LAG3 expression varies between
individual cells, potentially preventing its detection by bulk method-
ologies such as Western blotting despite robust expression by rare
single cells. We therefore performed immunofluorescence stainings
on NSC-derived human neural cultures. Again, no LAG3 could be
identified, whereas neural cultures lentivirally transduced with a
plasmid encoding LAG3 showed obvious positivity with two dif-
ferent antibodies (Fig 1G).
Subsequently, we investigated human brain areas for LAG3
expression. We selected post-mortem brain samples of Substantia
nigra and frontal cortex for immunoblotting. Activated T lympho-
cytes and lymphoepithelial tissue of tonsils were used as positive
controls due to their high expression of LAG3. Western blotting failed
to reveal the presence of LAG3 in human brain samples (Fig 1H).
Finally, we interrogated a single-nucleus (sn) RNAseq human
brain dataset that we have recently described (Saez-Atienzar et al,
2021) for LAG3 expression across different cell types. These data are
derived from 21 dorsolateral prefrontal cortices from 16 neurologi-
cally healthy donors (median age 36 years, range: 16–61 years,
male:female ratio = 1:1) and clustered and annotated using known
gene expression markers as specified (Saez-Atienzar et al, 2021).
We saw no LAG3 signals above background for any of 34 identified
cell clusters, including 13 clusters of excitatory and 11 subtypes of
inhibitory neurons, oligodendrocytes (ODC), oligodendrocyte
precursor cells (OPC), microglia (MGL), astrocytes (AST) and
endothelial cells (EC) (Fig 1I). Similar results were obtained by
examining available scRNAseq and snRNAseq datasets from juve-
nile and adult human brain tissue samples including Substantia
nigra (Zhang et al, 2016; Welch et al, 2019; Agarwal et al, 2020).
These results corroborate the absence of detectable LAG3 expression
in human neurons using snRNAseq.
Absence of endogenous LAG3 in murine brain samples
As the inability to detect LAG3 in human neuronal samples contra-
dicts previous observations (Mao et al, 2016), we analysed LAG3
expression in mouse brains. Prior RNAseq data reported that Lag3 is
poorly expressed in both hippocampus and cerebellum of WT mice
(Liu et al, 2018) and likely absent in murine neurons (Zhang et al,
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2014). Western blot of total brain homogenates from C57BL/6J
wild-type mice did not show any identifiable LAG3-specific band
(Fig 2A). Incubation with a different primary anti-LAG3 antibody
(Fig EV1C) and enrichment by immunoprecipitation (Fig EV2A)
confirmed the lack of LAG3 in wild-type mouse brain homogenates.
Next, we prepared mixed neuroglial and glial cortical cultures
from C57BL/6J mice and assessed LAG3 protein expression. The
anti-mitotic compound AraC was added to the mixed cortical
cultures to enrich for neurons and eliminate glia (Fig 2B, lower
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LAG3 in any of the samples, even after enrichment by immunopre-
cipitation with anti-mouse LAG3 antibody 4-10-C9 from 500 μg of
total protein (Fig EV2B). Using a LAG3 sandwich ELISA, we
assessed LAG3 expression in primary cultures, murine synaptoneu-
rosome preparations and brain region-specific preparations. We did
not find LAG3 expression in any of the samples, in contrast to acti-
vated T cells used for control (Fig 2C). Immunofluorescence stain-
ing of neuronally enriched primary cultures led to the same results,
with LAG3 being detectable only in the lentivirally transduced
cultures that were used as positive controls (Fig 2D).
We next quantified Lag3 mRNA from mixed neuroglial and glial
cortical cultures by RT–qPCR (Fig 2E). By interpolation of the thresh-
old cycle (CT) of each sample into a standard curve, we estimated
the presence of around 1–2 transcripts/ng of RNA in mixed cortical
cultures and neuron-enriched cultures, whereas in mixed glial
cultures, Lag3 mRNA was slightly more abundant (4–5 transcripts/
ng of RNA). These values are close to what we observed for a
LAG3−/− mouse brain homogenate (1–2 transcripts/ng of RNA) and
indicate that these Lag3 signals were nonspecific. In contrast, around
1,600 transcripts/ng of RNA were counted in activated T cells.
To further expand our analyses, we performed scRNAseq of
microdissected ventral midbrain and striatum of 1-year-old mice that
had been given a single striatal injection of PBS or LPS (n = 9 and 8,
respectively) as previously described (Russo et al, 2019). We then
assigned 76,305 cells to major cluster using markers (Fig EV2C). We
specifically investigated transcript levels of murine Lag3 in endothe-
lial cells, several macrophage subtypes (MPH), astrocyte subtypes,
red blood cells (RBC), vascular smooth muscle cells (VSMC), neural
precursor cells (NPC), microglia subtypes (MGL), oligodendrocyte
subtypes (ODC), T cells, neuron subtypes, oligodendrocyte precursor
cells (OPC), ependymal cells (Epnd), choroid plexus cells (ChP) and
fibroblasts (Fibr) (Fig EV2D). Of all identified murine cells, only
transmembrane protein 119 (TMEM119)-positive microglia showed
modest expression of Lag3, marginally above background (Fig 2F).
Of interest, the activation of microglia with lipopolysaccharide (LPS)
led to decreased expression of Lag3 in microglia (Fig EV2E).
However, and consistent with the negative results for detection of
LAG3 in human snRNAseq, we did not detect murine Lag3 in
neurons or astrocytes under any condition examined.
Promiscuous binding of α-synuclein fibrils questions selectivity
towards LAG3
The above observations suggest that the neuroprotective effects
exerted by antibodies to residues 52–109 of the LAG3 D1 domain, or
the depletion of LAG3 (Mao et al, 2016), may not be required for
the interaction between neuronal LAG3 and α-synuclein fibrils.
However, α-synuclein fibrils binding to LAG3 could still be an
important component involved in PD by an unknown mechanism.
To investigate the interaction between LAG3 and α-synuclein fibrils,
we performed ELISA by coating human LAG323-450, the human
LAG3 structural homologue, CD4 (Triebel et al, 1990; Bae et al,
2014), the microtubule-binding domain (MTBD) of human tau
protein, the prion protein PrPC, apolipoprotein E3 (APOE3), TAR
DNA-binding protein 43 (TDP-43), bovine serum albumin (BSA)
and arachis hypogaea 2 (Ara h 2), a major peanut allergen, to indi-
vidual wells of a microtiter plate. We then incubated ELISA plates
with serial dilutions (concentration of monomer equivalent:
125 nM–30 pM) of α-synuclein fibrils and filaments of apoptosis-
associated speck-like protein containing a CARD (ASC). If binding
occurs, the fibrils would be retained by the antigen and would be
detected by antibodies. ASC filaments yielded the expected dose–
response curves when directly coated onto microplates (Fig EV3)
but did not bind any of the proteins presented (Fig 3A). While α-
synuclein fibrils (but not monomeric α-synuclein) interacted with
LAG3, they exhibited similar binding to MTBD of human tau protein
and to CD4 (Fig 3B). PrPC, the APOE3 as well as TDP-43, was found
to interact less strongly, whereas BSA, Ara h 2 and uncoated condi-
tions did not display any binding in our system.
The observations detailed above suggest a promiscuous binding
of α-synuclein fibrils to many proteins including LAG3, MTBD and
CD4, suggestive of surface effects leading to nonspecific interac-
tions. We therefore employed a microfluidic-based technology (Aro-
sio et al, 2016; Scheidt et al, 2019; preprint: Schneider et al, 2020)
◀ Figure 1. Absence of expression of LAG3 in human brain cells.
A Binding of eight commercial antibodies to recombinant human LAG323-450 and murine LAG324-442 via indirect ELISA. Seven out of eight antibodies bound either
human or mouse LAG3, while one antibody (LSB15026) recognized both species.
B Specific detection of murine but not human LAG3 using 4-10-C9 anti-LAG3 antibody is confirmed with Western blotting.
C No detection of human LAG3 in neuronal or glial cell lines of human origin. The band for LAG3 was detected in activated T cells.
D No band for human LAG3 could be detected with Western blot in lysates of fully differentiated human NSC-derived neural cultures.
E Violin plot showing the RNA expression levels of human LAG3 in human NSC-derived neural cultures. Identities annotate different clusters: Neuronal clusters are
comprised of the following markers: GAD2, GABRG1, NTRK2, NEFM, SNCG, SLC17A6, SCN2A, DDIT3/HRK. Mixed glial clusters are defined by the following markers:
GFAP, S100B, STMN2, NRN1, GPM6B, COL1A1, with astrocyte-specific clusters characterized by GFAP, S100B, GPM6B, COL1A1. LAG3 cannot be evidenced in any of the
clusters beyond few random events. Data shown from 5,476 unique analysed cells from one out of two independent biological replicates.
F Dopaminergic neuronal cultures from control lines and glucocerebrosidase (GBA) N370S PD patients were immunoblotted for the presence of LAG3. No band for LAG3
could be observed in neurons.
G Using high power, high-resolution laser scanning confocal microscopy, no human LAG3 signal could be detected in human neurons (Auto-hLAG3 transduced, DOX
OFF) by two different anti-human LAG3 antibodies (17B4 and D2G40; left panel and zoomed-in insets) whereas LAG3 was clearly detected in human neurons induced
to express hLAG3 (DOX ON; right panel and zoomed-in insets). Scale bars 25 μm.
H Human brain homogenates from autopsy material were immunoblotted for the presence of LAG3. No band for LAG3 could be evidenced in any of the brain
homogenates. Control samples (tonsils and activated human T cells) show expected bands.
I Nuclei were isolated from 21 human dorsolateral prefrontal cortices from 16 donors, isolated and were subjected to snRNAseq. Expression levels were quantified and
are shown as violin plots. The LAG3 transcripts are non-detectable in all 34 distinct cell types, including multiple excitatory and inhibitory neurons, oligodendrocytes
(ODC), oligodendrocyte precursor cell (OPC) microglia (MGL), astrocytes (AST) or endothelial cells (EC). Cluster markers as detailed in Saez-Atienzar et al, 2021.
Source data are available online for this figure.
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to characterize the receptor-ligand interaction. Microfluidic diffu-
sional sizing (MDS) measures the hydrodynamic radius (Rh) of a flu-
orescently labelled protein and can characterize binding by
displaying an increase in Rh upon ligand binding. Increasing concen-
trations of α-synuclein fibrils did not induce a change in the hydro-
dynamic radius of fluorescently labelled LAG323–434, CD4 or BSA
(Fig 3C), whereas a labelled antibody directed against α-synuclein
(MJFR1) triggered the expected concentration-dependent size
increase. A progressive increase in the concentration of monomeric
α-synuclein did not lead to a rise in the hydrodynamic radius of
labelled LAG3; however, both anti-LAG3 antibody (Relatlimab) and
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al, 2019), displayed clear binding (Fig 3D), with affinities of
4.82  0.71 nM and 232  79 nM, respectively. Given that no
significant binding was detected, we conclude that the affinity of
LAG3 for α-synuclein fibrils, if any, is micromolar or less.
To shed light onto the interaction between α-synuclein fibrils and
LAG3, we performed co-immunoprecipitation experiments. SH-SY5Y
cells overexpressing hLAG3 were incubated with monomeric or fib-
rillary α-synuclein in live cells for 3 h at 37°C to allow binding at
the cell membrane. Then, immunoprecipitations with antibodies to
LAG3 or α-synuclein were performed. Immobilized LAG3 co-
precipitated α-synuclein fibrils, whereas co-precipitation with both
monomeric and fibrillar α-synuclein resulted in only a faint band for
LAG3 (Fig 3E and F). A major portion of both LAG3 and α-synuclein
fibrils remained in the unprecipitated soluble fraction.
Membrane-bound LAG3 does not affect the uptake and seeding
of α-synuclein PFFs in human neural cultures
The collective biochemical data presented above led us to question
whether there is a physiologically relevant interaction between α-
synuclein fibrils and LAG3. We therefore tested its functional rele-
vance in a human cell-based system. We differentiated NSCs into
human neural cultures previously shown to be devoid of LAG3
(Fig 1D and E) and transduced them with a lentivirus encoding
inducible expression of human LAG3. These cultures expressed α-
synuclein (Fig EV4A). We then added sonicated α-synuclein-pre-
formed fibrils (PFFs) (Volpicelli-Daley et al, 2014) and incubated
the cells with them for 14–28 days. Finally, we stained the phospho-
rylated form (pS129) of α-synuclein with two different phosphory-
lated α-synuclein-specific antibodies. We then compared the amount
of α-synuclein fibrils uptake and seeding through intracellular pS129
α-synuclein accumulation, in cultures that did not express (Fig
EV4B) or expressed (Fig EV4C) LAG3. We found no difference in
the proportion of cells containing pS129 α-synuclein between the
two conditions using the 81A (Fig 4A) or EPY1536Y anti-pS129 α-
synuclein antibodies (Fig 4B). Quantification of images using a
trained ilastik-based algorithm for pixel segmentation failed to show
any effects of LAG3 expression (Fig 4C and D). This suggests no
significant role for neuronal LAG3 in the uptake and, therefore, in
the downstream processes, including the transmission, of α-
synuclein fibrils in this paradigm.
Similar survival of ASYNA53T LAG3−/−, LAG3+/− or LAG3+/+ mice
Human LAG3 may be functionally dissimilar to its murine counter-
part. Hence, the negative data shown above do not negate an effect
of Lag3 in mice. We therefore examined the impact of LAG3 expres-
sion on the survival of mice expressing human α-synucleinA53T
under the transcriptional control of the mouse Thy1.2 promoter
(Van Der Putten et al, 2000). Since the expression of endogenous α-
synuclein is a key requirement for its propagation (Volpicelli-Daley
et al, 2014; Polinski et al, 2018), and since expression levels of α-
synuclein influence the propensity of aggregate formation
(Hayashita-Kinoh et al, 2006), we first assessed whether α-synuclein
expression is similar in ASYNA53T-expressing LAG3−/− and LAG3+/+
mice. No differences were found in cerebrospinal fluid (CSF)
collected from aged mice with Quanterix Single Molecule Arrays
(SIMOA) (Fig EV5), indicating that LAG3 does not modulate the
levels of the transgene.
We then bred ASYNA53T;LAG3−/−, ASYNA53T;LAG3+/-, ASYNA53T;
LAG3+/+ and nontransgenic LAG3−/− mice (n = 8, 9, 13 and 8,
respectively, including males and females). All mice expressing
ASYNA53T, but none of the nontransgenic LAG3−/− mice, developed
severe α-synucleinopathy and were sacrificed with a median
survival of A53T α-synuclein mice of 263 days regardless of LAG3
genotype (95% CI: 240–277; Fig 5A). Consistent with these results,
LAG3 knockout did not induce histologically detectable changes in
the mesencephalic distribution patterns of pS129 α-synuclein or
thioflavin S-positive aggregates (Fig 5B) of end-stage symptomatic
mice. These results suggest that LAG3 plays little, if any, role in the
propagation of α-synuclein pathology in vivo.
No difference in pS129 α-synuclein in hippocampal organotypic
slice cultures of A53T LAG3−/− or LAG3+/+ mice
The effect of LAG3 in mice may be contingent on the utilization of
α-synuclein PFFs as a seed. Alternatively, LAG3 may influence early
α-synuclein lesion formation without modifying the survival or the
end-stage pathology of mice. To this end, we cultured hippocampal
slices of A53T α-synuclein TG or α-synuclein WT mice KO or WT
for LAG3, respectively, and inoculated them with 5 μg α-synuclein
PFFs. Organotypic slices were kept in culture for 5 weeks, and the
pS129- or thioflavin S-positive area was assessed (Barth et al, 2021).
◀ Figure 2. Absence of expression of LAG3 in mouse brain cells, particularly in neurons.
A Brain homogenates from LAG3 KO and WT mice were immunoblotted for the presence of murine LAG3. Western blot does not show a specific band other than for
activated murine T cells.
B Mixed neuroglial, neuron-enriched and glial cortical cultures were assayed for the presence of LAG3 where no band could be found. Activated T cells display band at
expected size.
C Lysates of synaptoneurosomes (SNS) of different brain regions and mouse brain region-specific areas as well as murine activated T cells were assayed for the
presence of LAG3 with sandwich ELISA. No evidence for LAG3 could be found in any of the samples other than in activated T cells. Expression is shown in pg LAG3 per
μg total protein as mean values of technical quadruplicates with 95% confidence intervals.
D Using high power, high-resolution laser scanning confocal microscopy, no mouse LAG3 signal could be detected in murine primary neuronal cultures (Auto-mLAG3
transduced, DOX OFF and non-transduced neurons) using anti-mouse LAG3 antibody (MABF954) whereas LAG3 was clearly detected in primary neurons induced to
express mLAG3 (Auto-mLAG3 transduced, DOX ON). Scale bars 20 μm.
E RT–qPCR-derived CT values to measure the cDNA copy number. Mixed neuroglial cultures, glial cultures and neuron-enriched cultures show transcript levels that are
close to indistinguishable to those from LAG3−/− BH. Conversely, around 1,600 transcripts/ng of RNA were counted in activated T cells.
F Murine mesencephalon and striatum of 1-year-old mice (n = 17 in total) were interrogated with scRNAseq. Violin plot showing expression values of Lag3, in 76,305
assigned cells, between identified cell clusters, mainly expressed in TMEM119-positive microglia cells. Cluster markers are detailed in Russo et al, 2019.
Source data are available online for this figure.
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Non-seeded organotypic slices did not show any sign of pS129 α-
synuclein (Fig 5C) or thioflavin S positivity (Fig 5D), while seeded
α-synuclein WT slices showed moderate pS129 α-synuclein- or thio-
flavin S-positive areas and A53T slices had more prominent pathol-
ogy, as previously reported (Barth et al, 2021). However, no
significant difference was found between LAG3 KO and WT in slices
derived from A53T transgenic or wild-type mice, indicating that
LAG3 does not play an essential role in the uptake and propagation
of α-synuclein PFFs in this system.
Discussion
LAG3 was named a selective receptor for pathogenic α-synuclein
assemblies using an exhaustive series of in vitro and in vivo experi-
ments with a variety of genetic and pharmacological tools (Mao
et al, 2016). Yet, there is little evidence for a role of LAG3 in human
α-synucleinopathies (Liu et al, 2018; Cui et al, 2019; Guo et al,
2019). This situation prompted us to revisit the interaction between
LAG3 and α-synuclein conformers. When assessing cell lines,
NSC-derived neural cultures or organ homogenates for the presence
of human or murine LAG3, we selected antibodies appropriate to
the species investigated and, whenever possible, have used multiple
antibodies to increase the confidence in our results. We were unable
to detect LAG3 in any of the neuronal samples tested. Thus, we felt
the need to investigate further using a broader array of techniques:
Western blotting, sandwich ELISA, immunofluorescence, RT–qPCR,
snRNAseq and scRNAseq. None of these methods were able to
detect endogenous LAG3 expression in human neurons. The most
parsimonious interpretation of these collective data is that human
neurons do not express LAG3 at appreciable levels. One notable
exception is our scRNAseq dataset of mouse ventral midbrain
detecting low expression of LAG3 in microglia, in accordance with
previous reports (Tasic et al, 2016; Galatro et al, 2017).
It is unclear whether the lack of detection of LAG3 in human
microglia relates to a crucial species difference or to technical limita-
tions of snRNAseq versus scRNAseq, which may be particularly
important for microglia (Thrupp et al, 2020). Either way, these data
and other available data sets (Zhang et al, 2014, 2016; Welch et al,




































































































































Figure 3. Characterization of binding properties between α-synuclein PFFs and LAG3 reveals promiscuous character of α-synuclein.
A, B Binding of ASC filaments (A) or α-synuclein PFFs (B) to multiple proteins. Serial dilutions of ASC filaments and α-synuclein PFFs were performed, and bound
fractions were detected using anti-ASC or anti-α-synuclein (MJFR1) antibodies. ASC filaments did not interact with any of the proteins (A). Conversely, α-synuclein
PFFs strongly bound LAG3, CD4 and MTBD tau and showed moderate binding properties to PrPC, APOE3 and TDP-43. No binding between α-synuclein PFFs and
nAra h 2 or BSA could be detected. Values represent means  SD of technical duplicates.
C, D Diffusional sizing of α-synuclein PFFs with fluorescently conjugated LAG3, CD4, BSA and MJFR1 α-synuclein antibody (C) and of fluorescently labelled LAG3 with
monomeric α-synuclein, α-synuclein PFFs, FGL1 and Relatlimab anti-LAG3 antibody (D). An increase in the hydrodynamic radius (Rh) of α-synuclein PFFs is seen
with increasing concentrations for MJFR1 but not for LAG3 or any of the control proteins, also not at a lower scale (see insert) (C). Similarly, the hydrodynamic
radius of labelled LAG3 increases with higher concentrations of Relatlimab and FGL1 but does not change with α-synuclein PFFs or monomeric α-synuclein (D).
Values are given as means  SD of technical triplicates.
E, F Co-immunoprecipitation of LAG3 and subsequent immunoblotting with anti-α-synuclein antibody (MJFR1) (E) and co-immunoprecipitation of α-synuclein
(monomeric or PFFs) and subsequent immunoblotting with anti-LAG3 antibody (D2G40) (F). Using the anti-α-synuclein antibody for pulldown resulted in LAG3
bands with both monomeric as well as fibrillar α-synuclein. The usage of anti-LAG3 for pulldown led to the specific detection of α-synuclein PFFs, although the PFF
fraction predominates also in the input and supernatant. Bands for α-synuclein (E) and LAG3 (F) are indicated by arrows.
Source data are available online for this figure.
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expression of neuronal LAG3, at least using current technology for
single-cell analysis. Thereby, we question one of the foundations of
the hypothesis proposed by Mao et al, (2016) and discussed else-
where (Jucker & Heikenwalder, 2016; Wood, 2016; Wong & Krainc,
2017).
A possible confounder may be the cross-immunoreactivity of
antibodies between murine and human LAG3, which appears to be
rare. Within a collection of commercial anti-LAG3 antibodies, only
one out of 8 anti-LAG3 antibodies reacted with both human as well
as murine LAG3. Mao et al. immunoblotted the human HEK293FT
and SH-SY5Y cell lines alongside mouse cortical cultures using an
anti-LAG3 antibody (4-10-C9, MABF954) that appears to specifically
recognize LAG3 of murine origin (see supplementary figure 5 in
Mao et al, 2016).
LAG3 could plausibly play a role in the pathogenesis of α-
synucleinopathies, e.g. via complex formation with soluble LAG3
(Guo et al, 2019) and subsequent endocytosis by hitherto unidenti-
fied neuronal receptors or via targeting immune checkpoints of T
cells (Baruch et al, 2016; Schwartz, 2017; Liu & Aguzzi, 2019)
despite not being pulled down upon brief exposure of mouse
primary neurons and astrocytes to α-synuclein fibrils (Shrivastava
et al, 2015). The interaction between LAG3 and fibrillary α-
synuclein is therefore of interest. α-Synuclein fibrils, in contrast to
apoptosis-associated speck-like protein containing a CARD (ASC),
are promiscuous; yet, they bind some proteins much better than
others. LAG3, the microtubule-binding domain of human tau and
CD4, interacted more than PrPC, APOE3 and TDP-43, whereas BSA
and Ara h 2 showed even less interaction. However, the binding of
α-synuclein fibrils to CD4 stands in direct opposition to data
presented earlier (Mao et al, 2016). FGL1, a recently reported inter-
action partner of LAG3 (Wang et al, 2019), could be confirmed to
bind LAG3 with microfluidic diffusional sizing (MDS), with an
A
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Figure 4. Propagation of α-synuclein PFFs in vitro is not dependent on LAG3 in human NSC-derived neural cultures.
Human neural cultures transduced by Auto-hLAG3 were treated by α-synuclein PFFs 4 days post-LAG3 expression induction by DOX and kept in culture for 2 or 4 weeks.
Both transgenic (hLAG3 D2G40-positive in (A) and 17B4-positive in (B)) and non-transduced, wild-type neurons (selected neurons in zoomed-in insets) propagated α-
synuclein and developed characteristic pS129-positive (81A-positive in (A) and EP1536Y-positive in (B)) α-synuclein aggregates. Scale bars 25 μm. Trained ilastik
algorithms were used to segment pixels of 81A, EP1536Y and MAP2 stainings imaged by high-content widefield microscope, which were used to quantify the signal of
81A-positive (C) and EP1536Y-positive (D) α-synuclein aggregates expressed as % of MAP2-positive area. Almost the entire wells (182 fields per well) were imaged for
every condition and replicate, and each datapoint in the plot represents the entire well. Error bars indicate mean  SD of biological replicates (duplicates). For few
conditions, unicates were used, shown as one dot. One-way ANOVA followed by Tukey’s multiple comparison test demonstrated that neurons that did not express LAG3
(DOX OFF) showed no difference in α-synuclein propagation when compared to LAG3-expressing neurons (DOX ON) as demonstrated by two different pS129 α-synuclein
antibodies (P = 0.9998 for 81A at 2 weeks and P = 0.2522 at 4 weeks; P = 0.9986 for EP1536Y at 2 weeks and P = 0.3042 at 4 weeks).
Source data are available online for this figure.
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affinity of 232  79 nM, slightly higher than a previous assessment
with Octet bio-layer interferometry analysis suggested (Wang et al,
2019). On the other hand, MDS failed to reproduce data obtained
by ELISA, as no binding between LAG3 and α-synuclein fibrils
occurred, nor with CD4 and α-synuclein fibrils. This could indicate
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fibrils or FGL1. A possible explanation is that a single α-synuclein
fibril binds to multiple LAG3 molecules through electrostatic and/
or hydrophobic interactions, resulting in cooperative unspecific
interactions that can be captured with ELISA where proteins are
immobilized, but not with MDS.
A pulldown experiment confirmed the weak interaction between
LAG3 and α-synuclein fibrils. Due to the promiscuous binding of α-
synuclein fibrils, their specificity to LAG3 seems questionable.
Experiments performed by Mao et al (2016) indicate that LAG3−/−
reduces α-synuclein fibril binding in cortical neurons by maximally
10% (see figure 1D, in Mao et al (2016)). In the original report, mean
values in LAG3−/− primary cortical neurons differ only at high α-
synuclein fibril-biotin concentrations and display a relatively high
standard error (Mao et al, 2016), suggesting that there was no
biologically important difference. This is not surprising in view of
LAG3 not being expressed in neuronal cultures, so its ablation
should not have an effect. Our experiments in human neural cultures
point in the same direction as we could not identify any significant
difference in pS129-positive aggregates upon expression of LAG3,
strongly suggesting that other neuronal factors, some of which we
identified through a pulldown approach (Shrivastava et al, 2015),
mediate the uptake and transmission of α-synuclein fibrils.
The negative findings discussed above do not preclude a modula-
tory role for LAG3 in α-synucleinopathies through other mecha-
nisms. We investigated whether LAG3 ablation changes the
propensity of α-synuclein aggregation in vivo and, importantly,
whether it affects the overall survival of α-synuclein-overexpressing
mice. However, our study conducted in A53T human α-synuclein
TG mice KO, hemizygous or WT for LAG3 showed that neither lifes-
pan nor deposition of α-synuclein aggregates is significantly
changed upon the presence or absence of LAG3, leaving little hope
that LAG3 would assume a role in α-synuclein-related pathologies.
Experiments with hippocampal organotypic slice cultures inoculated
with α-synuclein PFFs did not change this perception to the better
and do not seem to converge with the notion that LAG3 contributes
to α-synucleinopathy in different A53T human α-synuclein mice (Gu
et al, 2021).
Parkinson’s disease and other pathologies underlying the spread
of α-synuclein aggregates are severe neurodegenerative diseases
with momentous implications on the lives of patients and their fami-
lies. More work is needed to understand how α-synuclein is
transmitted from cell to cell, to identify selective receptors for propa-
gating forms of α-synuclein and to subsequently enable a targeted
treatment. Until then, potential targets need to be rigorously vetted,
bearing in mind that attrition of futile approaches is crucial to avoid-
ing high opportunity costs.
Materials and Methods
Usage of human material
All experiments and analyses involving samples from human donors
were conducted with the approval of the local ethics committee
(BASEC-2020-00234), in accordance with the provisions of the
Declaration of Helsinki, the Department of Health and Human
Services Belmont Report and the Good Clinical Practice guidelines
of the International Conference on Harmonisation. Informed consent
was obtained from all individuals if applicable. The local ethics
committee issued a clearance certificate/declaration of no-objection
when fully anonymized human samples were used.
Animal work
Mice housing were in accordance with the Swiss Animal Welfare
Law and in compliance with the regulations of the Cantonal Veteri-
nary Office, Zurich (permits 033/2018, 236/2019). Mice were bred
in high hygienic grade facilities and housed in groups of 3–5, under
a 12-h light/12-h dark cycle (from 7 am to 7 pm) at 21  1°C, with
sterilized food (Kliba No. 3431, Provimi Kliba, Kaiseraugst, Switzer-
land) and water ad libitum. For primary culture, we used 8- to 9-
week-old C57BL/6J mice. When needed, two pregnant females
(E14) were delivered and housed in the animal facility of the
University of Zurich.
A53T-α-synuclein (Thy1-hA53T-αS) (Van Der Putten et al, 2000)
and LAG3 KO (B6.129S2-LAG3tm1Doi/J) (Miyazaki et al, 1996)
animals were bred and kept under specific pathogen-free conditions
at the Hertie Institute for Clinical Brain Research in T€ubingen,
Germany, with sterilized food and water ad libitum. For estimation
of survival rates, genders were balanced within the groups, whereas
only female mice were used for immunological and Thioflavin S
staining. LAG3 KO mice were initially purchased from Jackson
◀ Figure 5. Survival in A53T α-synuclein mice and aggregation of α-synuclein in vivo and in hippocampal slice cultures is independent from LAG3 expression.
A Survival curves of A53T α-synuclein TG mice, with LAG3 knockout, heterozygous LAG3 expression, or LAG3 WT. Median survival was shortest for α-synuclein TG LAG3−/−
at 239 days, followed by α-synuclein TG LAG3+/− at 260 days and α-synuclein TG LAG3+/+ at 268 days. The survivals of ASYNA53T LAG3−/−, LAG3+/− and LAG3+/+ mice
were similar (Mantel–Cox log-rank test, P-value = 0.165). Mice were euthanized and dissected in the late-stage symptomatic phase, which would inevitably result in
death within a week. None of the control LAG3−/− α-synuclein WT mice died over the course of the experiment.
B Immunostaining for hyperphosphorylated α-synuclein aggregates (pS129) and aggregated protein (Thioflavin S) in sections of end-stage symptomatic mice; no
obvious difference in terms of staining pattern or number of stained cells was apparent in midbrain or brain stem. Scale bars represent 1 mm (sagittal section) and
100 μm (panel).
C Immunofluorescence staining and quantification of pS129-positive α-synuclein inclusions in hippocampal slice cultures (HSCs) at 5 weeks post-seeding with 350 μM
PFF. Scale bars represent 500 μm (overview), and 100 μm (insets). Shown is mean  SEM, and individual values are shown; n = 6 cultures per group; two-way-
ANOVA revealed for LAG3 F(1, 20) = 0.0294; P = 0.8656; A53T F(1, 20) = 36.42, P < 0.0001; interaction F(1, 20) = 0.0062, P = 0.9382. Bonferroni’s correction for
multiple comparisons revealed P = 0.9973 for LAG3 WT versus KO in A53T TG and P > 0.9808 for LAG3 WT versus KO in A53T WT.
D Immunofluorescence staining and quantification of Thioflavin S-positive α-synuclein inclusions in HSCs at 5 weeks post-seeding. Scale bars represent 500 μm
(overview), and 100 μm (insets). Shown is mean  SEM, and individual values are shown; n = 5–6 cultures per group; two-way-ANOVA revealed for LAG3 F(1,
19) = 1.972, P = 0.1763; A53T F(1, 19) = 62.49, P < 0.0001; interaction F(1, 19) = 1.586, P = 0.2231. Bonferroni’s correction for multiple comparisons revealed
P = 0.1373 for LAG3 WT versus KO in A53T TG and P > 0.9999 for LAG3 WT versus KO in A53T WT.
Source data are available online for this figure.
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Laboratories (Bar Harbor, ME, USA) and crossed to our internal
strains to generate the various genotypes used in this study. The
experimental procedures were carried out in accordance with the
veterinary office regulations of Baden-Wuerttemberg (Germany) and






Primary neuronal cell cultures were prepared from brains of E16-17
mouse embryos. Briefly, hippocampus and cortex were isolated in
PBS-Glucose (D-Glucose, 0.65 mg/ml). The tissue was treated with
trypsin (0.5% w/v) in PBS-Glucose and dissociated in Neurobasal
Medium (NB) supplemented with glutamine (2 mM), 2% B27, 2%
N2, 100 U penicillin–streptomycin (P/S) and D-Glucose (0.65 mg/
ml). In order to obtain a mixed culture, the medium was supple-
mented with 2.5% Horse Serum for the first 24 h in vitro, while for
neuronal-enriched culture, cells were treated with 5 μM cytosine
arabinoside (AraC) from DIV 1 to DIV 6. For biochemical experi-
ments, cells were then plated onto poly-D-lysine coated 6-well plate
(TPP-92006) at 8 × 105 cells/cm2. For imaging, cells were plated
onto poly-D-lysine-coated chambered coverglass (NuncTM Lab-
TekTM - 155411) at 2 × 105 cells/cm2. For both types of culture,
only one-half of the medium was exchanged every 3–4 days. When
lentiviral transduction was used to generate LAG3-expressing
cultures, cells were transduced at DIV 6 and fixed at DIV 13.
Primary glia cell cultures were prepared from postnatal (P4-P6)
pups. Briefly, hippocampus and cortex were isolated. The tissue
was treated with trypsin (0.5% w/v) in HBSS-Glucose (D-Glucose,
0.65 mg/ml) and triturated with glass pipettes to dissociate tissue in
DMEM/F12 (31330038) supplemented with glutamine (2 mM), 5%
horse serum and 100 U penicillin–streptomycin, 100 μM non-
essential amino acid and 2 mM sodium pyruvate. For biochemical
experiments, cells were plated 6-well plate (TPP-92006) at 8 × 105
cells/cm2. For imaging, cells were plated onto chambered coverglass
(NuncTM Lab-TekTM-155411) at 2 × 105 cells/cm2.
Synaptoneurosome preparations and region-specific dissections
of murine brains
Synaptosome fractions were prepared following the protocol
performed as described earlier (De Rossi et al, 2020). Briefly,
cortices, striata and hippocampi were dissected from the brains of
adult C57BL/6J mice and resuspended in cold buffer containing
0.32 M sucrose and 10 mM HEPES at pH 7.4 and centrifuged twice
(at 770 ×g) to remove nuclei and large debris, followed by centrifu-
gation at 12,000 × g to obtain the synaptosome fraction. The
synaptosomes were washed and pelleted in EDTA buffer to chelate
calcium (4 mM HEPES, 1 mM EDTA, pH 7.4, 20 min at
12,000 × g). The synaptosomes were resuspended in the lysis
buffer for 1 h on ice (20 mM HEPES, 0.15 mM NaCl, 1% Triton
X-100, 1% deoxycholic acid, 1% SDS, pH 7.5) and stored at −80°C.
Region-specific dissections (cortex, hippocampus, olfactory bulb,
corpus callosum, midbrain, striatum, hindbrain, cerebellum) were
performed in the same mice and solubilized in 20 mM HEPES,
0.15 mM NaCl, 1% Triton X-100, 1% deoxycholic acid, 1% SDS,
pH 7.5 and stored at −80°C.
Isolation and activation of mouse T lymphocytes
T lymphocytes were isolated from the spleen of C57BL/6J mice
using a negative selection isolation kit (EasySep™ Mouse T Cell
Isolation Kit, StemCell Technologies). Cells were plated in a 48-well
plate (Corning) previously coated with anti-mouse CD3 (clone
#17A2, PeproTech) and anti-mouse CD28 (clone #37.51, PeproTech)
antibodies and incubated in IMEM medium supplemented with IL-2
at 37°C. After 3 days, the activated T lymphocytes were collected
and processed for either RNA extraction or Western blotting. The
expression of mLAG3 was checked by Western blotting using
mLAG3-transfected HEK cells as positive control.
Isolation and activation of human T lymphocytes
Fully anonymized residual full blood samples were collected at the
Institute of Clinical Chemistry (USZ) using a workflow outlined
previously (preprint: Emmenegger et al, 2020), and peripheral blood
mononuclear cells (PBMCs) were isolated using a Ficoll gradient.
PBMCs were resuspended in RPMI medium supplemented with 10%
FBS, 1× P/S, 1× non-essential amino acids (Gibco) and 1× sodium
pyruvate (Gibco), to reach a concentration of 2 million cells per ml.
2 ml cell suspension/well was added into a 24-well plate. 1 ml
medium was removed every second day, and 1 ml RPMI medium
with supplements as listed above as well as with 100 international
units IL-2 and 2 μg/ml phytohemagglutinin (PHA) was added. T
cells were cultured between 7 and 9 days. Finally, the medium was
removed, 100 μl lysis buffer (50 mM Tris, pH 8, 150 mM NaCl, 1%
Triton, protease and phosphatase inhibitors) was added to each well
and multiple wells were pooled. Following a centrifugation step
(16,000 g, 20 min, 4°C), the supernatant was transferred to a clean
tube and the protein concentration measured using the BCA assay.
Lentivirus preparation, transduction and SH-SY5Y cell
line generation
Using NEBuilder HiFi DNA Assembly Cloning Kit (NEB #E5520),
human or mouse LAG3 cDNA sequence (GeneCopoeia #EX-Z5714-
M02 and #EX-Mm03576-M02) was inserted into an autoregulatory,
all-in-one TetON cassette (AutoTetON; Hruska-Plochan et al, 2021),
which was previously inserted into a pLVX lentiviral transfer vector
(Clontech # 632164), while deleting CMV-PGK-Puro, generating
Auto-hLAG3 and Auto-mLAG3 lentiviral transfer vectors. These
were then packaged into lentivirus via co-transfection with CMV-
Gag-Pol (Harvard #dR8.91) and pVSV-G (Clontech, part of #631530)
plasmids into production HEK293T cells adapted to grow in serum-
free conditions (OHN media Hruska-Plochan et al, 2021), which
reduces the expression of the GOI from the transfer vector as well as
it eliminates serum carry over into the supernatant. Medium was
changed the following morning, and supernatants were then
collected 48 h post-transfection (36 h postmedia change),
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centrifuged at (500 g, 10 min, 4°C), filtered through Whatman 0.45-
μm CA filter (GE #10462100) and concentrated using Lenti-X™
Concentrator (Takara #631232) according to producer datasheet
(overnight incubation). The resulting lentiviral pellets were then
resuspended in complete neuronal maturation media or OHN media
to achieve 10× concentrated LV preparations, which were titrated
using Lenti-X™ GoStix™ Plus (Takara #631280). Auto-hLAG3 had a
GoStix Value (GV) of 6496 and Auto-mLAG3 had GV of 12839.
Transduction of NSC-derived human neural cultures
Differentiated human neural cultures (2 months old) were trans-
duced with 250 μl of Auto-hLAG3 LV and 3 μg/ml of polybrene
(Sigma-Aldrich #TR-1003-G) per well of a 6-well plate. Medium was
exchanged completely the following day. hLAG3 expression was
induced by 1 μg/ml of Doxycycline (DOX; Clontech #631311).
Transduction of SH-SY5Y cells to generate SH-10 line inducibly
expressing hLAG3
SH-SY5Y human neuroblastoma cells (Sigma-Aldrich #94030304) at
P11 were transduced in a 6-well plate using 300 μl of Auto-hLAG3
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Table 2. Details on antigens used in current study.
Name Experiment
Human APOE3, PeproTech (#350-02) ELISA with fibrils
Human ASC-C-his, produced by Matthias Geyer
(Bonn)
ELISA with fibrils




Human LAG323–434, BonOpusBio (#CJ91) MDS




Natural Ara h 2 (NA-AH2-1), Light roasted peanut
flour (Runner cultivar), Indoor Biotechnologies
ELISA with fibrils
Human recombinant PrPC, produced in-house
(Adriano Aguzzi)
ELISA with fibrils
Bovine serum albumin (BSA), Thermo Scientific ELISA with fibrils,
MDS
FGL1 Protein, Human, Recombinant, 13484-
H08B, Sino Biological
MDS
Human α-synuclein, produced in-house (Kelvin
Luk)
ELISA with fibrils
Human CD4, ACROBiosystems (#LE3-H5228) ELISA with fibrils,
MDS
MTBD tau, produced in-house (Adriano Aguzzi) ELISA with fibrils
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LV pre-incubated with 30 μl of Lenti-X™ Accelerator (Clontech
#631256) for 30 min. The LV mixture was added onto the cells,
evenly spread over the whole well and put into incubator onto a
neodymium magnetic sheet (supermagnete #NMS-A4-STIC; adhe-
sive force of 450 g/cm²) for 10 min. Cells were then removed from
the incubator, LV mixture was completely removed, and fresh SH
media added. Cells were kept until confluency and then sub-
cultured with the neodymium magnet sheet kept under the plate. To
remove remaining magnetic beads, cell pellet was resuspended in
1.5 ml of SH media, pipetted into 1.5-ml Eppendorf tube and
inserted into DynaMag™-2 Magnet (Invitrogen #12321D). Cell
suspension was then removed from the tube leaving all magnetic
beads in the tube. Quantification of P11+1 SH-10 cells showed that
76% of cells were expressing hLAG3 upon induction by 1 μg/ml of
Doxycycline (DOX; Clontech #631311). This decreased to 59% in
P11+2 and remained around 50% in the following passages. P11+3
was used for all experiments except for the CO-IP, where a later
passage was used.
Maintenance of NSC-derived neural cultures
Human neural stem cells derived from iPSCs using manual selection
based on colony morphology (Bohaciakova et al, 2019)—
iCoMoNSCs (Hruska-Plochan et al, 2021)—were differentiated for
2 months resulting in functional neural networks (Hruska-Plochan
et al, 2021). Shortly, iCoMoNSCs were plated onto Matrigel-coated
6-well plates and grown in NSC media until reaching confluency.
Media was then changed to D3 differentiation media, which was
replaced for maturation media at 4 weeks of differentiation. For
imaging experiments, cultures were dissociated into single-cell
suspension using Papain Dissociation System (Worthington
#LK003150), passed through 70-μm cell strainer (Falcon #07-201-
431), resuspended in maturation media and re-plated into 96-well
imaging plate (Greiner Bio-One #655090) at 120,000 cells per well
as counted by CASY Cell Counter (Innovatis AG).
scRNAseq in NSC-derived neural cultures—Sample preparation
Differentiated human neural cultures (3 months old) were dissoci-
ated into single-cell suspension using Papain Dissociation System
(Worthington #LK003150), passed through 70-μm and 40-μm cell
strainers (Falcon #07-201-431 and #07-201-430) and resuspended in
HIBE++ media (Hibernate™-E Medium (Gibco #A1247601) supple-
mented with EDTA (1mM final; Invitrogen #AM9260G), HEPES
(10 mM final; Gibco #15630080), with 1× B27+ supplement (Gibco
#17504-044), 1X N2 supplement (Gibco #17502-048); 1× GlutaMAX
(Gibco #35050-061), BDNF (PeproTech #450-02), GDNF (Alomone
labs #G-240), CNTF (Alomone labs #C-240), NT-3 (PeproTech #450-
03) and IGF-1 (Stem Cell #78022) all at 20 ng/ml to 1,000 cells per
μl using to CASY Cell Counter (Innovatis AG).
scRNAseq in NSC-derived neural cultures using 10X
Genomics platform
The quality and concentration of the single-cell preparations were
evaluated using an haemocytometer in a Leica DM IL LED micro-
scope and adjusted to 1,000 cells/μl. 10,000 cells per sample were
loaded into the 10× Chromium controller, and library preparation
was performed according to the manufacturer’s indications (Chro-
mium Next GEM Single Cell 3ʹ Reagent Kits v3.1 protocol). The
resulting libraries were sequenced in an Illumina NovaSeq
sequencer according to 10× Genomics recommendations (paired-
end reads, R1 = 28, i7 = 8, R2 = 91) to a depth of around 50,000
reads per cell. The sequencing was performed at Functional Geno-
mics Center Zurich (FGCZ).
scRNAseq data analysis in NSC-derived neural cultures—Cell
clustering and differential expression on each sample
The fastq files were aligned to the Homo Sapiens reference sequence
(build GRCh38.p13) taken from Ensembl. After the alignment, each
observed barcode, UMI, gene combination was recorded as a UMI
count matrix that was then filtered to remove low RNA content cells
or empty droplets using the CellRanger software (v3.0.1). Starting
from this matrix we used the R package Seurat (version 3.1.5) (But-
ler et al, 2018) to perform the following downstream analyses per
sample: genes and cells filtering, normalization, feature selection,
scaling, dimensionality reduction, clustering and differential expres-
sion. We started by filtering out genes that did not obtain at least 1
UMI count in at least 3 cells, and discarded cells for which fewer
than 1,500 genes or more than 8,000 genes were detected and also
those that had a mitochondrial genome transcript ratio > 0.12. After
this, the data were normalized using a global-scaling normalization
method that normalizes the feature expression measurements for
each cell by the total expression, multiplies this by a scale factor
(10,000 by default) and log-transforms the result. We next calcu-
lated a subset of 2,000 features that exhibited high cell-to-cell varia-
tion in the data set. Using as input these variable features, we
performed PCA on the scaled data. Since Seurat clusters cells based
on their PCA scores, we used a heuristic method called “Elbow plot”
to determine how many principal components (PCs) we needed to
capture the majority of the signal. In this way, the cells were clus-
tered with an unsupervised graph-based clustering approach using
the first 30 first PCs and a resolution value of 0.5. Clusters were
visualized using t-distributed Stochastic Neighbor Embedding of the
principal components (spectral t-SNE) or Uniform Manifold Approx-
imation and Projection for Dimension Reduction (UMAP) as imple-
mented in Seurat. We found positive markers that defined clusters
compared to all other cells via differential expression. The test we
used was the Wilcoxon rank-sum test which assesses separation
between the expression distributions of different clusters. Genes
with an average, at least 0.25-fold difference (log-scale) between the
cells in the tested cluster and the rest of the cells, and an adjusted
P < 0.01 were declared as significant. Cell cycle phases were
predicted using a function included in the scran R package (Lun et
al, 2016) that scores each cell based on expression of canonical
marker genes for S and G2/M phases. To visually, qualitatively and
quantitatively interrogate expression of particular genes in all cells
amongst all clusters via t-SNE, UMAP, violin and distribution plots,
we used a custom-built Shiny application.
Propagation experiment in NSC-derived neural cultures: PFF-
induced synuclein aggregation and aggregates quantification
Human neural cultures were transduced as described above. 4 days
later, neural cultures were sub-cultured into 96-well plates as
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described above. hLAG3 expression was then induced by addition
of 1 μg/ml of Doxycycline (DOX; Clontech #631311) 3 weeks
(4 weeks of DOX on conditions) or 5 weeks (2 weeks of DOX on
conditions) later. 4 days post-hLGA3 expression activation, 500 nM
of human exogenous α-synuclein pre-formed fibrils (PFFs) produced
from monomeric recombinant α-synuclein by Kelvin Luk Lab as per
(Volpicelli-Daley et al, 2014) was added to half of the wells (result-
ing in 8 conditions: 2 weeks of DOX+/−/ PFFs+/− (n = 4 wells per
condition) and 4 weeks of DOX+/−/ PFFs+/− (n = 5 wells per condi-
tion). 50 μl of fresh media was added 4 days and then again 6 days
later, and 50% of media was exchanged on day 8 of the treatment
and then three times a week until the end of the experiment while
refreshing the DOX at 1 μg/ml.
Propagation experiment in NSC-derived neural cultures: Fixation,
immunofluorescence and imaging
Neural cultures were fixed with pre-warmed 16% methanol-free
formaldehyde (Pierce #28908) pipetting it directly into the culture
media, diluting it to 4% final, and incubated for 15 min at room
temperature. Cells were then washed once with PBS (Gibco
#10010015) for 10 min, once with PBS with 0.2% Triton X-100
(TX; Sigma #T9284) washing buffer (WB) for 10 min and then
blocked with 10% normal donkey serum (Sigma-Aldrich #S30-M),
0.2% TX in PBS blocking buffer filtered via Stericup (Millipore
#S2GPU02RE) for 30 min at room temperature (RT). Primary anti-
bodies were then diluted in blocking buffer (81A 1:500; D2G40
1:500; MAP2 Abcam #ab5392; EP1536Y 1:500; 17B4 1:500; MJFR1
1:1,000) and left incubated overnight (ON) at 4°C on an orbital
shaker. Cells were then washed 3 × 15 min in WB at RT, and
secondaries were then diluted in blocking buffer (Donkey anti-
rabbit AF568 (Invitrogen #A10042) 1:750; Donkey anti-mouse
AF488 (Invitrogen #A-21202) 1:750; Donkey anti-chicken AF647
(Jackson Immuno Research #JAC703-606-155) 1:500) and incu-
bated for 1.5 h at RT. Cells were then again washed 3 × 15 min in
WB at RT with DAPI (Thermo Scientific #62248) diluted to 1 ug/ml
in the final WT wash. Cells were finally washed 1 × 15 min in PBS
at RT, and PBS was then added to the wells to store the stained
cells at 4°C. Human neural cultures were imaged using GE InCell
Analyzer 2500 HS widefield microscope for quantification (40× air
objective; 2D acquisition; 182 fields of view per well; 50 μm separa-
tion to avoid counting cells twice) or with Leica SP8 Falcon
inverted confocal for high power, high-resolution microscopy (63×
oil objective; 2,096 × 2,096 pixels at 0.059 μm/pixel, approx. 20–30
z-steps per stack at 0.3 μm). Laser and detector setting were kept
same for each staining combination and all imaged conditions.
Huygens professional (Scientific Volume Imaging, Hilversum,
Netherlands) was then used to deconvolute the stacks, and the
deconvoluted images were further post-processed in fiji to produce
a flattened 2D pictures (Z-projection) for data visualization.
Propagation experiment in NSC-derived neural cultures:
signal quantification
Trained ilastik (Berg et al, 2019) algorithms were used to segment
the pixels (positive versus background) of 81A, EP1536Y and MAP2
stainings. Segmented pictures (182 images per well, per channel)
were then exported and the total signal quantified in fiji via batch
processing using a custom macro. Sum of all positive pixels of all
182 fields of view per well for 81A and EP1536Y was then expressed
as % of total MAP2 area occupied by 81A or EP1536Y signal. Statis-
tical analysis was performed in Prism (GraphPad San Diego, CA,
USA), and one-way ANOVA followed by Tukey’s multiple compar-
ison test was applied on the datasets.
Propagation experiment in NSC-derived neural cultures: PFF
preparation and treatment
PFFs were sonicated before their addition to the neural cultures as
follows: stock PFFs at 5 mg/ml were diluted in PBS (Gibco #
10010015) inside of a standard 0.5-ml Eppendorf tube to 0.1 mg/ml
reaching 250 μl final volume. The diluted PFFs were then sonicated
using ultrasonic processor (Qsonica #Q500A-110) equipped with a
cup horn (Qsonica #431C2) allowing for indirect sonication via
high-intensity ultrasonic water bath using the following settings:
Amplitude 40%, 30 cycles of 2-s on, 2-s off (resulting in total run
time of 120 s; 60-s sonication, 60-s off). Ice-cold water was freshly
poured into the cup immediately before the sonication. 210 μl of
sonicated PFFs was further diluted in 2790 μl of pre-warmed
complete maturation media (reaching 500 nM) and added to the
neural cultures (250 μl per well; all spent media was removed
before treatment).
snRNA sequencing in human frontal cortex
Single nuclei RNA sequencing (snRNAseq) analysis of human
frontal cortex was completed as previously described (Saez-Atienzar
et al, 2021). In brief, frozen frontal cortex tissue samples from 16
donors in the North American Brain Expression Consortium study
series (dbGaP Study Accession: phs001300.v1.p1, (Myers et al,
2007)) were obtained from the University of Maryland Brain and
Tissue Bank through the NIH NeuroBioBank. Nuclei were isolated
from 21 total samples from the 16 donors by ultracentrifugation
through a sucrose gradient, and the Chromium Single Cell Gene
Expression Solution v3 (10× Genomics) was used to construct
snRNAseq libraries. Libraries were pooled and sequenced using the
Illumina NextSeq 550 System. The resulting FASTQ files were
aligned and counted using Cell Ranger v3 (10× Genomics). The 21
data sets were integrated, and clustering analysis was performed
using Seurat v3.1 (Stuart et al, 2019) in R. Cell clusters comprised of
a total of 161,225 nuclei were manually assigned cell type identities
based on differential expression of known cell type marker genes.
The cell type abbreviations are as follows: “EC” = endothelial cell;
“AST” = astrocyte; “MGL” = microglia; “OPC” = oligodendrocyte
precursor cell; “ODC” = oligodendrocyte; “InN” = inhibitory
neuron; “ExN” = excitatory neuron.
scRNA sequencing in mouse mesencephalon and striatum
Single-cell suspensions were generated from the midbrain and stria-
tum of 1-year-old animals. All the animals have received a single
intra-striatal injection with either lipopolysaccharide (LPS) or
phosphate-buffered saline (PBS) and were sacrificed 48 h after
surgery as described previously (Russo et al, 2019). Brain areas
were dissociated using Adult Brain Dissociation Kit (Miltenyi Biotec
#130-107-677) following by myelin removal with 20-μl myelin
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removal beads (Miltenyi Biotec #130-096-733). Cell concentration
and viability of the single-cell solutions were determined on LunaFL
cell counter (Logos Biosystems) and adjusted to 1,000 cells per μl.
Preparations had more than 85% viability and were kept on ice
prior to single-cell encapsulation and library preparation. For encap-
sulation, 8,500 cells per sample were loaded into a Single-Cell 30
Chip of the 10× Chromium controller and libraries were generated
using 10xGenomics (Chromium Next GEM Single Cell 3ʹ Reagent
Kits v3.1 protocol). The resulting libraries were examined by Agilent
Bioanalyzer 2100 using a High Sensitivity DNA chip (Agilent).
Libraries were sequenced at NIH Intramural Sequencing Center
(NISC, Bethesda, USA) on an Illumina NovaSeq600 sequencer, using
S4 flow cell format according to 10× Genomics recommendations
(2 × 150 bp, paired-end reads, Read1 = 28, i7 Index = 8, Read2 =
91) with an estimated read depth of 100,000 reads per cell.
Sequencing data were analysed using the Cell Ranger Pipeline
(version v3.1.0) to perform quality control, sample demultiplexing,
barcode processing, alignment and single-cell 30 gene counting.
Genome Reference Consortium Mouse Build 38 (GRCm38-mm10)
Mus musculus reference transcriptome was used for alignment.
Single-cell data from PBS- or LPS-treated animals were combined
into a single Seurat object and filtered for genes detected in more
than three cells and for cells that had more than 500 genes (fea-
tures). These data sets were normalized using SCTransform v0.2.1
and integrated by pair-wise comparison of anchor gene expression
within the Seurat package v3.1 in R (Butler et al, 2018). Shared
nearest neighbour-based clustering was used to identify distinct cell
clusters, which were then manually assigned cell type identities
based on differential expression of known cell type marker genes.
iPSC-derived dopaminergic cultures
iPSCs were differentiated as previously described (Bengoa-
Vergniory et al, 2020). Dopaminergic neuronal cultures from control
lines and GBA N370S PD patients were harvested at 35DIV and
stained for TH (ab152, Millipore) or harvested for Western blotting.
Western blotting
Whole mouse brains were homogenized in RIPA buffer, whereas
mouse primary cortical cultures and activated T lymphocytes were
lysed in lysis buffer (50 mM Tris, 150 mM NaCl, 1% Triton X-100)
containing protease and phosphatase inhibitors (Roche, New York,
NY, USA). Total protein contents were quantified using the BCA
assay (Pierce). For Western blotting, total proteins were separated
on SDS–polyacrylamide gels (4–12%, Invitrogen) and transferred
onto PVDF membranes. Membranes were blocked in 5% SureBlock
(LubioScience) for 1 h at RT and incubated overnight at 4°C with
anti-LAG3 mouse monoclonal antibody 4-10-C9 (1:1,000).
Membranes were washed three times with PBS-Tween and incu-
bated with goat-anti-mouse IgG conjugated with horseradish peroxi-
dase (1:10,000). The acquisition was performed using ECL
Crescendo substrate (Merck Millipore) and imaged with Fusion Solo
S (Vilber). After the acquisition, the membranes were incubated for
30 min at RT with anti-β-actin (1:10,000, A3854 Sigma-Aldrich),
which was used as a loading control.
For IP enrichment, 500 μg of total proteins of mouse brain homo-
genates and primary cultures and 10 μg of total proteins of activated
T lymphocytes were incubated overnight with 50 μl of Dynabeads™
(Thermo Fisher) previously conjugated with 4-10-C9 antibody.
Beads were washed three times with PBS, resuspended in Laemmli
buffer and dissociated by boiling for 5 min at 95°C. The super-
natants were loaded onto SDS–polyacrylamide gels and processed
as described above. Target antigens were detected using an anti-
LAG3 rabbit polyclonal antibody (1:1,000, B15026) and goat-anti-
rabbit IgG conjugated to horseradish peroxidase (HRP) (1:1,000).
Mouse LAG3 Sandwich ELISA
High-binding 384-well SpectraPlates (Perkin Elmer) were coated
with mouse mAb 4-10-C9 at a concentration of 1 μg/ml in sterile
PBS and at a volume of 20 μl/well. The plates were incubated for
1 hr at 37°C and washed 3× with 1× PBS 0.1% Tween-20. Plates
were then blocked with 5% milk in 1× PBS 0.1% Tween-20
(40 μl/well) and incubated for 1 h at RT. The blocking buffer was
subsequently removed. The cell lysates/organ homogenates were
added at a total protein concentration of 1,000 μg/ml (or, if indi-
cated, at 500 μg/ml due to insufficient sample concentration),
20 μl/well, in quadruplicates and mouse recombinant LAG324–442,
was added at 5 μg/ml at highest concentration, 40 μl/well into the
first well of the dilution series, and a 15-fold 1:2 serial dilution of
the recombinant proteins was performed (end volume for each
well: 20 μl). The buffer used for sample dilution: 1% milk in 1×
PBS 0.1% Tween-20. The plates were incubated for 1 h at RT,
followed by a 3× wash with 1x PBS 0.1% Tween-20. To detect the
presence of LAG3, we used rat mAb C9B7W (for mouse LAG3), at
1 μg/ml and at 20 μl/well. The plates were incubated for 1 h at
RT, followed by a 5× wash with 1× PBS 0.1% Tween-20. To
detect the presence of the detection antibody, we used HRP-anti-
rat IgG (1:2,000, for mouse LAG3, HRP Donkey anti-rat IgG
(H + L), 712-035-153, Jackson), at volume of 20 μl/well. The
plates were then incubated for 1 h at RT and washed 3× with 1×
PBS 0.1% Tween-20. TMB was dispensed at a volume of 20 μl/
well, followed by a 5-min incubation, and the stop solution (0.5 M
H2SO4) was added at a volume of 20 μl/well. The absorbance at
450 nm was read on the EnVision (Perkin Elmer) reader. Finally,
the measured optical densities were interpolated (independently
for all replicates) using the mouse recombinant LAG3 standards
(values that are in the linear range) and LAG3 expression per μg
total protein was depicted for all samples.
RNA extraction and RT–qPCR
Mouse primary cultures were collected and lysed in lysis buffer and
TRIzol LS Reagent in a ratio 1:3. Samples were supplemented with
0.2 ml of chloroform per 1 ml of TRIzol and centrifugated. The
aqueous phase was collected, and the RNA was precipitated with
subsequent addition of isopropanol and ice-cold 75% ethanol.
Pellets were resuspended in ultrapure, RNAse-free water and quanti-
fied at the NanoDrop. Genomic DNA elimination and reverse tran-
scription were performed using QuantiTect Reverse Transcription
Kit (Qiagen) according to manufacturer’s instructions.
To generate a standard curve for transcript quantification, a
commercial plasmid encoding full-length mouse LAG3 CDS (Gene-
Copoeia, Mm0357-02) was used as standard. The number of DNA
molecules in 1 μl was calculated using the following formula:
ª 2021 The Authors EMBO Molecular Medicine 13: e14745 | 2021 15 of 20







numberbpvectorþLAG3amplicon bpð Þ 109 650
Serial dilutions of the standard containing known numbers of
molecules and 25 ng of total cDNA of the samples were amplified in
RT–qPCR using mouse LAG3-specific primers (Liu et al, 2018). The
number of transcripts per ng of RNA was calculated by interpolating
the threshold cycle values of the samples into the standard curve
and then dividing by the ng of RNA used in the RT–qPCR.
ELISA with fibrils
High-binding 384-well SpectraPlates (Perkin Elmer) were coated
with proteins of interest at a concentration of 1 μg/ml in sterile PBS
and at a volume of 20 μl/well. The plates were incubated for 1 h at
37°C and washed 3× with 1× PBS 0.1% Tween-20. Plates were then
blocked with 5% SureBlock (Lubio) in 1× PBS 0.1% Tween-20
(40 μl/well) and incubated for 1 h at RT. The blocking buffer was
subsequently removed. Monomer equivalents of fibrils (α-synuclein
or ASC) were added at a concentration of 0.125 μM, 20 μl/well and
a 13-fold 1:2 serial dilution was performed (end volume for each
well: 20 μl). The buffer used for sample dilution: 1% SureBlock in
1× PBS 0.1% Tween-20. The plates were incubated overnight at
4°C, followed by a 5× wash with 1× PBS 0.1% Tween-20. In a
control experiment, monomer equivalents of fibrils (α-synuclein or
ASC) were coated onto high-binding 384-well SpectraPlates (Perkin
Elmer) as serial dilutions (13-fold 1:2 serial dilution), starting at a
concentration of 0.125 μM, in sterile PBS and at a volume of 20 μl/
well, incubated for 1 h at 37°C, washed 3× with 1× PBS 0.1%
Tween-20 and blocked with SureBlock. Next, antibodies directed
against the fibrils or monomeric proteins were added at 1 μg/ml and
at 20 μl/well, in sample buffer. The plates were incubated for 1 h at
RT, followed by a 3× wash with 1× PBS 0.1% Tween-20. To detect
the presence of the detection antibody, we used HRP-anti-rabbit IgG
(1:2,000, HRP Goat anti-Rabbit IgG (H + L), 111-035-045, Jackson),
at volume of 20 μl/well. The plates were then incubated for 1 h at
RT and washed 3× with 1× PBS 0.1% Tween-20. TMB was
dispensed at a volume of 20 μl/well, followed by a 5-min incuba-
tion, and the stop solution (0.5 M H2SO4) was added at a volume of
20 μl/well. The absorbance at 450 nm was read on the EnVision
(Perkin Elmer) reader, and the respective curves were plotted in
GraphPad Prism.
Microfluidic diffusional sizing
Microfluidic diffusional sizing (MDS) measurements were
performed as reported previously (Arosio et al, 2016; Wright et al,
2018; Scheidt et al, 2019). Briefly, microfluidic devices were fabri-
cated in polydimethylsiloxane (PDMS) applying standard soft-
lithography methods and subsequently bonded onto a glass micro-
scopy slide after activation with oxygen plasma. Samples and buffer
were loaded onto the chip from sample reservoirs connected to the
inlets and the flow rate controlled by applying a negative pressure
at the outlet using a glass syringe (Hamilton, Bonaduz, Switzerland)
and a syringe pump (neMESYS, Cetoni GmbH, Korbussen,
Germany). Imaging was performed using a custom-built inverted
epifluorescence microscope supplied with a charge-coupled-device
camera (Prime 95B, Photometrics, Tucson, AZ, USA) and brightfield
LED light sources (Thorlabs, Newton, NJ, USA). Lateral diffusion
profiles were recorded at 4 different positions along the microfluidic
channels. Varying fractions of unlabelled ligands were added to a
solution containing labelled receptors of concentrations varying
between 10 nM and 10 μM, and PBS (containing 0.01% Tween-20,
SA) was added to give a constant volume of 30 μl. The samples
were incubated at room temperature for 60 min, and the size of the
formed immunocomplex was determined through measuring the
hydrodynamic radius, Rh, with microfluidic diffusional sizing, as
described above. Dissociation constants (KD) were determined using















with [L]tot the concentration of ligand added, [X]0 the concentra-
tion of labelled protein, KD the dissociation constant, α the stoi-
chiometric binding ratio, ΔR the difference in radius between fully
bound and fully unbound and R0 the radius of fully unbound
labelled protein.
Co-immunoprecipitation
SH-SY5Y cells expressing human LAG3 under the control of a
doxycycline-inducible promoter were plated in 6-well plates and
treated with doxycycline (1 μg/ml) for 72 h to induce the expression
of LAG3. Monomeric and fibrillar α-synuclein (1 μM) and PBS (neg-
ative control) were added to the culture medium and incubated for
3 h at 37°C. Cells were lysed in lysis buffer (50 mM Tris, pH 8,
150 mM NaCl, 1% Triton, protease and phosphatase inhibitors),
and 500 μg of total proteins was further processed. 30 μl was
collected from each sample and used as control inputs. Samples
were pre-incubated with Dynabeads Protein G to eliminate any
possible material that could bind unspecifically to the beads. Subse-
quently, samples were incubated with Dynabeads functionalized
with either anti-α-synuclein or anti-LAG3 antibody and left over-
night on a rotor wheel at 4°C. The day after, beads were collected,
resuspended in Laemmli buffer and boiled for 5 min to dissociate
the precipitated fractions. Supernatants were then loaded onto an
SDS–PAGE and processed as described above.
Immunofluorescence
Primary cultures were fixed at DIV 12-14 with 4% PFA supple-
mented with 4% sucrose, followed by incubation in 10% donkey
serum + 0.2% Triton X-100 for 1 h at room temperature. For
immunostaining, antibodies were diluted in blocking buffer (anti-
MAP2 1:1,000; anti-GFAP 1:1,000; anti-LAG3 4-10-C9 1:1,000; anti-
Iba1 1:1,000) and incubated overnight at 4°C. Samples were then
washed 3 times with PBS and incubated with fluorescently conju-
gated secondary antibodies (1:400) and DAPI (1:10,000).
Preparation and treatment of hippocampal slice cultures
HSCs were prepared from pups at postnatal days 4–6 (P4-6) accord-
ing to previously published protocols (Novotny et al, 2016). After
16 of 20 EMBO Molecular Medicine 13: e14745 | 2021 ª 2021 The Authors
EMBO Molecular Medicine Marc Emmenegger et al
decapitation, the brains of the pups were aseptically removed, and
the hippocampi were dissected and cut perpendicular to the longi-
tudinal axis into 350-μm sections with a tissue chopper. Carefully
selected intact hippocampal sections were transferred into petri
dishes containing ice-cold buffer solution (minimum essential
medium (MEM) supplemented with 2 mM GlutaMAX™ at pH 7.3).
Three sections were placed onto a humidified porous membrane in
a well of a 6-well plate with 1.2 ml culture medium (20% heat-
inactivated horse serum in 1× MEM complemented with
GlutaMax™ (1 mM), ascorbic acid (0.00125%), insulin (1 μg/ml),
CaCl2 (1 mM), MgSO4 (2 mM) and D-glucose (13 mM) adjusted to
pH 7.3). HSCs were kept at 37°C in humidified CO2-enriched atmo-
sphere. The culture medium was changed three times per week.
HSCs were kept for 10 days without any experimental treatment.
At day 10, 1 μl of PFF (5 μg/μl) was pipetted on top of each
culture.
α-Synuclein PFF preparation
We used protocols developed by the Melki and the Luk laboratories.
In the Melki protocol, expression in E. coli, purification and quality
control of human recombinant monomeric wt α-synuclein was done
as described (Bousset et al, 2013). For fibril formation, soluble wt α-
synuclein was incubated in Tris–HCl buffer (50 mM Tris–HCl, pH
7.5, 150 mM KCl) at 37°C under continuous shaking for 5 days and
formation of fibrils was assessed with Thioflavin T. The fibrils were
quality checked by transmission electron microscopy after negative
staining before and after fragmentation. Their limited proteolytic
pattern was also assessed (Bousset et al, 2013). The average size of
the fibrils after fragmentation 47  5 nm was derived from length
distribution measurements, and their average molecular weight
(16,200 Da) was derived from analytical ultracentrifugation sedi-
mentation velocity measurements. The fibrils (350 μM) were
aliquoted (6 μl per tube), flash-frozen in liquid nitrogen and stored
at −80°C.
In the Luk protocol, expression in E. coli, purification and qual-
ity control of human recombinant monomeric wt α-synuclein and
assembly into PFFs was done as described (Luk et al, 2009;
Volpicelli-Daley et al, 2014). α-synuclein was expressed in E. coli
and purified to reach a final concentration of monomeric α-
synuclein of around 30 mg/ml. Monomeric α-synuclein in 1.5-ml
microcentrifuge tubes at a volume of 500 μl and a final concentra-
tion of 5 mg/ml was assembled into α-synuclein PFFs by shaking
for 7 days at 1,000 RPM in a thermomixer at 37°C. The quality of
the fibrils was assessed as detailed earlier (Volpicelli-Daley et al,
2014).
Analysis of human α-synuclein expression in CSF of A53T LAG3−/−
and LAG3+/+ animals using SIMOA
Samples of the cerebrospinal fluid (CSF) were collected in a stan-
dardized manner adapted from the methodology of the Alzheimer’s
Association external quality control programme used for human
CSF (Mattsson et al, 2011) as described previously (Schelle et al,
2017). Sampling was performed under a dissecting microscope.
Mice were deeply anaesthetized with a mixture of ketamine
(100 mg/kg) and xylazine (10 mg/kg) and placed on a heat pad to
maintain a constant body temperature during the whole procedure.
After incision of the overlying skin and retraction of the posterior
neck muscles, the dura mater covering the cisterna magna was care-
fully cleaned with cotton swabs, PBS and ethanol. In case of microb-
leeds in the surrounding tissue, hemostyptic gauze (Tabotamp,
Ethicon) was used to keep the dura mater spared from any blood
contamination. Finally, the dura was punctured with a 30G needle
(BD Biosciences) and CSF was collected with a 20 μl gel loader tip
(Eppendorf, shortened), transferred into 0.5-ml polypropylene tubes
(Eppendorf) and placed on ice. Typically, a total volume of 15–25 μl
was collected per mouse. The samples were centrifuged for 10 min
at 2,000× g, visually inspected for any pellet revealing blood
contamination, aliquoted (5 μl) and stored at –80°C until further
usage. Samples with suspected blood or cell contamination were not
used for any further experiments. CSF α-synuclein concentrations
were measured by Single Molecule Array (SIMOA) technology using
the SIMOA Human Alpha-Synuclein Discovery Kit according to the
manufacturer’s instructions (Quanterix, Billerica, MA, USA). Mouse
CSF samples were diluted 1:300 with Alpha-Synuclein Sample Dilu-
ent before the measurement and analysed on a SIMOA HD-1
Analyzer in duplicates.
Histology and Immunohistochemistry
Brains were cut in 25 μm-thick sagittal sections on a freeze-sliding
microtome (Leica SM 2000R) and subsequently emerged in cryopro-
tectant (35% ethylene glycol, 25% glycerol in PBS) and stored on
−20°C. Hippocampal cultures were fixed after 5 weeks of cultivation
period with 4% paraformaldehyde (PFA) in 0.1 M phosphate buffer
(PB), pH 7.4 for 2 h. Cultures were rinsed three times with 0.1 M
PBS for 10 min. The Millipore membrane with the fixed cultures
was cut out and mounted onto a planar agar block. The cultures
were sliced into 50-μm sections with a vibratome. Antigen retrieval
was enhanced by heating the sections in 10 mM citrate buffer
(1.8 mM citric acid, 8.2 mM trisodium citrate [pH 6.0]; 90°C;
35 min). For detection of α-synuclein phosphorylated at ser-129, we
used a rabbit monoclonal pS129 antibody (Abcam, EP1536Y,
1:1,000) and followed the standard protocols provided with the
VECTASTAIN Elite ABC Kit and the SG blue kit (Vector Laborato-
ries, USA) (brain sections) or used an Alexa-fluorophore-conjugated
secondary antibody (goat-anti-rabbit Alexa-568; Thermo Fisher,
A11011) in a concentration of 1:250 (slice cultures). For Thioflavin
S staining, sections were incubated for 5 min with freshly prepared
filtered Thioflavin S solution (3% w/v Thioflavin S in Milli-Q
H2O) and washed 2× in 70% EtOH and 3× in Milli-Q H2O for
10 min each.
Quantification of immunohistochemical stainings in
slice cultures
For the quantification of the pS129-positive inclusions in HSCs,
whole culture mosaic images were acquired on an Axioplan 2 imag-
ing microscope (Plan Neofluar 10×/0.50 objective lens; Zeiss).
Images were blinded, colour channels were split, background was
subtracted (rolling ball radius 50 pixels), and the intensity threshold
was manually adjusted. On each mosaic, the percentage of pS129-
positive signal over the whole culture was calculated. Statistical
analysis was done with GraphPad Prism (v.9), using unpaired two-
tailed t test.
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Data availability
The raw data underlying this study will be made available upon
request. While the availability of human or murine samples is
limited, we will be doing our utmost to share material provided
strong scientific rationale. This study includes no data deposited in
external repositories.
Expanded View for this article is available online.
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